FIELD: medicine, oncology, pharmacy.
SUBSTANCE: invention relates to drugs and concerns docetaxel as a drug used in accessory therapy for treatment of metastatic cancer breast in combination with doxorubicin and cyclophosphamide. Proposed combination of drugs provides the enhanced viability coefficient in patients with superexpressed glands ER, PR and/or HER2.
EFFECT: enhanced effectiveness of treatment.
6 cl, 36 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PERSONALIZED ASSIGNMENT OF NEOAJUVANT CHEMOTHERAPY TO PATIENTS SUFFERING FROM LUMINAL TYPE B BREAST CANCER | 2015 |
|
RU2594251C1 |
| METHOD OF TREATING PATIENTS WITH METASTASES IN LYMPH NODES AND OLIGOMETASTATIC DISEASE IN BONES OF SKELETON IN PROSTATE CANCER | 2018 |
|
RU2695348C2 |
| METHOD OF TREATMENT BREAST CANCER | 2008 |
|
RU2393888C1 |
| METHOD OF TREATING PATIENTS WITH BRCA-ASSOCIATED TRIPLE-NEGATIVE LOCALLY ADVANCED BREAST CANCER | 2023 |
|
RU2814578C1 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| METHOD FOR TREATING LUMINAL SUBTYPE OF BREAST CANCER | 2018 |
|
RU2706029C1 |
| APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER | 2021 |
|
RU2806277C1 |
| TREATING THREE RECEPTOR NEGATIVE BREAST CANCER | 2007 |
|
RU2448697C2 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
